PURPOSE: To compare the effects of the two novel, potent, nonsteroidal aromatase inhibitors anastrozole and letrozole on total-body aromatization and plasma estrogen levels. PATIENTS AND METHODS: Twelve postmenopausal women with estrogen receptor-positive, metastatic breast cancer were treated with anastrozole 1 mg orally (PO) and letrozole 2.5 mg PO once daily, each given for a time interval of 6 weeks in a randomized sequence. Total-body aromatization was determined before treatment and at the end of each treatment period using a dual-label isotopic technique involving isolation of the metabolites with high-performance liquid chromatography. Plasma levels of estrone (E(1)), estradiol (E(2)), and estrone sulfate (E(1)S) were determined in samples obtained before each injection using highly sensitive radioimmunoassays. RESULTS:Pretreatment aromatase levels ranged from 1.68% to 4.27%. On-treatment levels of aromatase were detectable in 11 of 12 patients during treatment with anastrozole (mean percentage inhibition in the whole group, 97.3%) but in none of the 12 patients during treatment with letrozole (> 99.1% suppression in all patients; Wilcoxon, P =.0022, comparing the two drug regimens). Treatment with anastrozole suppressed plasma levels of E(1), E(2), and E(1)S by a mean of 81.0%, 84.9%, and 93.5%, respectively, whereas treatment with letrozole caused a corresponding decrease of 84.3%, 87.8% and 98.0%, respectively. The suppression of E(1) and E(1)S was found to be significantly better during treatment with letrozole compared with anastrozole (P =.019 and.0037, respectively). CONCLUSION: This study revealed letrozole (2.5 mg once daily) to be a more potent suppressor of total-body aromatization and plasma estrogen levels compared with anastrozole (1 mg once daily) in postmenopausal women with metastatic breast cancer.
RCT Entities:
PURPOSE: To compare the effects of the two novel, potent, nonsteroidal aromatase inhibitors anastrozole and letrozole on total-body aromatization and plasma estrogen levels. PATIENTS AND METHODS: Twelve postmenopausal women with estrogen receptor-positive, metastatic breast cancer were treated with anastrozole 1 mg orally (PO) and letrozole 2.5 mg PO once daily, each given for a time interval of 6 weeks in a randomized sequence. Total-body aromatization was determined before treatment and at the end of each treatment period using a dual-label isotopic technique involving isolation of the metabolites with high-performance liquid chromatography. Plasma levels of estrone (E(1)), estradiol (E(2)), and estrone sulfate (E(1)S) were determined in samples obtained before each injection using highly sensitive radioimmunoassays. RESULTS: Pretreatment aromatase levels ranged from 1.68% to 4.27%. On-treatment levels of aromatase were detectable in 11 of 12 patients during treatment with anastrozole (mean percentage inhibition in the whole group, 97.3%) but in none of the 12 patients during treatment with letrozole (> 99.1% suppression in all patients; Wilcoxon, P =.0022, comparing the two drug regimens). Treatment with anastrozole suppressed plasma levels of E(1), E(2), and E(1)S by a mean of 81.0%, 84.9%, and 93.5%, respectively, whereas treatment with letrozole caused a corresponding decrease of 84.3%, 87.8% and 98.0%, respectively. The suppression of E(1) and E(1)S was found to be significantly better during treatment with letrozole compared with anastrozole (P =.019 and.0037, respectively). CONCLUSION: This study revealed letrozole (2.5 mg once daily) to be a more potent suppressor of total-body aromatization and plasma estrogen levels compared with anastrozole (1 mg once daily) in postmenopausal women with metastatic breast cancer.
Authors: Natalie J Engmann; Christopher G Scott; Matthew R Jensen; Lin Ma; Kathleen R Brandt; Amir Pasha Mahmoudzadeh; Serghei Malkov; Dana H Whaley; Carrie B Hruska; Fang Fang Wu; Stacey J Winham; Diana L Miglioretti; Aaron D Norman; John J Heine; John Shepherd; V Shane Pankratz; Celine M Vachon; Karla Kerlikowske Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-02-01 Impact factor: 4.254
Authors: James N Ingle; Junmei Cairns; Vera J Suman; Lois E Shepherd; Peter A Fasching; Tanya L Hoskin; Ravinder J Singh; Zeruesenay Desta; Krishna R Kalari; Matthew J Ellis; Paul E Goss; Bingshu E Chen; Bernhard Volz; Poulami Barman; Erin E Carlson; Tufia Haddad; Matthew P Goetz; Barbara Goodnature; Matthew E Cuellar; Michael A Walters; Cristina Correia; Scott H Kaufmann; Richard M Weinshilboum; Liewei Wang Journal: Clin Cancer Res Date: 2020-02-25 Impact factor: 12.531
Authors: Jason D Robarge; Zereunesay Desta; Anne T Nguyen; Lang Li; Daniel Hertz; James M Rae; Daniel F Hayes; Anna M Storniolo; Vered Stearns; David A Flockhart; Todd C Skaar; N Lynn Henry Journal: Breast Cancer Res Treat Date: 2016-12-09 Impact factor: 4.872
Authors: N Lynn Henry; Anna Conlon; Kelley M Kidwell; Kent Griffith; Jeffrey B Smerage; Anne F Schott; Daniel F Hayes; David A Williams; Daniel J Clauw; Steven E Harte Journal: J Pain Date: 2014-01-22 Impact factor: 5.820
Authors: Anne E Lykkesfeldt; Katrine L Henriksen; Birgitte B Rasmussen; Hironobu Sasano; Dean B Evans; Susanne Møller; Bent Ejlertsen; Henning T Mouridsen Journal: BMC Cancer Date: 2009-06-16 Impact factor: 4.430